Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 101–200 of 2,656
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 92
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 84
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Empagliflozin in Patients with Chronic Kidney Disease
Neuen, B. L., Fletcher, R. A., & Heerspink, H. J. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2301923 · Cited by 77
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis
Neuen, B. L., Fletcher, R. A., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Inzucchi, S. E., Jardine, M., Mahaffey, K. W., et al. (2025) · JAMA · doi:10.1001/jama.2025.20834 · Cited by 120
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03339-3 · Cited by 93
Sharma, A., Ferreira, J. P., Zannad, F., Pocock, S. J., Filippatos, G., Pfarr, E., Petrini, M., Kraus, B. J., Wanner, C., Packer, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2857 · Cited by 71
Podocyte-targeted therapies — progress and future directions
Meliambro, K. A., He, C., & Campbell, K. N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00843-z · Cited by 93
Chronic Kidney Disease — Another Step Forward
August, P. (2023) · New England Journal of Medicine · doi:10.1056/nejme2215286 · Cited by 74
Gullaksen, S., Vernstrøm, L., Sørensen, S. S., Ringgaard, S., Laustsen, C., Funck, K. L., Poulsen, P. L., & Laugesen, E. (2023) · Diabetologia · doi:10.1007/s00125-023-05876-w · Cited by 75
“Based on our results, we therefore speculate that improved medullary oxygenation is not a driver for the nephroprotective effects seen in CREDENCE [4], DAPA-CKD [5] or EMPA-KIDNEY [6].”
ResultGenitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Kittipibul, V., Cox, Z. L., Chesdachai, S., Fiuzat, M., Lindenfeld, J. M., & Mentz, R. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.040 · Cited by 103
Hypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Santulli, G., Varzideh, F., Forzano, I., Wilson, S. M., Salemme, L., Donato, A. D., Lombardi, A., Rainone, A., Nunziata, L., Jankauskas, S. S., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20598 · Cited by 84
Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074545 · Cited by 70
Sattar, N., Presslie, C., Rutter, M. K., & McGuire, D. K. (2024) · Diabetes Care · doi:10.2337/dci23-0041 · Cited by 70
Cardiorenal benefits of finerenone: protecting kidney and heart
González‐Juanatey, J. R., Górriz, J. L., Ortíz, A., Valle, A., Soler, M. J., & Fácila, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2171110 · Cited by 95
IgA nephropathy in adults—treatment standard
Gleeson, P. J., O'Shaughnessy, M. M., & Barratt, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad146 · Cited by 90
“The Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) [24 ] and Empagliflozin in Patients with Chronic Kidney Disease (EMPA-Kidney) [25 ] studies clearly document the reno-protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in proteinuric chronic kidney disease…”
BackgroundLovegrove, C. E., Howles, S., Furniss, D., & Holmes, M. V. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae136 · Cited by 95
Metabolic Rewiring and Communication: An Integrative View of Kidney Proximal Tubule Function
Chrysopoulou, M., & Rinschen, M. M. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042222-024724 · Cited by 85
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 87
“Empagliflozin had beneficial effect on the primary renal outcome in EMPA-KIDNEY (HR 0.72, 95% CI 0.64–0.82) (Table 1 ) [ 58 ].”
BackgroundInfluentialPrevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 67
Armillotta, M., Angeli, F., Paolisso, P., Belmonte, M., Raschi, E., Dalmazi, G. D., Amicone, S., Canton, L., Fedele, D., Suma, N., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108861 · Cited by 84
Francis, S., Selby, N. M., & Taal, M. W. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.02.007 · Cited by 74
Moriconi, D., Sacchetta, L., Chiriacò, M., Nesti, L., Forotti, G., Natali, A., Solini, A., & Tricò, D. (2023) · Diabetes Care · doi:10.2337/dc22-2003 · Cited by 72
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
Dai, Z.-C., Chen, J., Zou, R., Liang, X.-B., Tang, J., & Yao, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213473 · Cited by 84
“Clinical trials such as DAPA-CKD, EMPA-KIDNEY, SOCRED, and CREDENCE have demonstrated no increased risk of hypoglycemia in patients with stage G4 DKD (9, 10, 85, 88).”
BackgroundInfluentialNew Insight in Cardiorenal Syndrome: From Biomarkers to Therapy
Gallo, G., Lanza, O., & Savoia, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065089 · Cited by 84
Seidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 97
Torrá, R., Lipska-Ziętkiewicz, B. S., Acke, F. R. E., Antignac, C., Becker, J. U., Gall, É. C.-L., van Eerde, A. M., Feltgen, N., Ferrari, R., Gale, D. P., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae265 · Cited by 72
“The trials included less than 0.3% patients younger than 40 years of age with an eGFR > 60 ml/min/1.73 m² [89 , 90 ].”
InfluentialRenal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Kim, D., Lee, S., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1629 · Cited by 73
“001) in patients with CKD; the results were consistent among subgroups based on baseline diabetes and eGFR range (Table 2) [76].”
ResultKidney fibrosis: Emerging diagnostic and therapeutic strategies
Klinkhammer, B. M., & Boor, P. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101206 · Cited by 68
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 81
Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease
Byun, J. H., Lebeau, P. F., Trink, J., Uppal, N., Lanktree, M. B., Krepinsky, J. C., & Austin, R. C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00938-1 · Cited by 84
“Current treatments for CKD — renin–angiotensin–aldosterone system inhibitors (ACE inhibitors and angiotensin receptor blockers (ARBs)), sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) 160 — all appear to modify ER stress in the kidney.”
Chen, X., Delić, D., Cao, Y., Shen, L., Shao, Q., Zhang, Z., Wu, H., Hasan, A. A., Reichetzeder, C., Gaballa, M. M. S., et al. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00528.2022 · Cited by 67
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 77
“EMPA-Kidney (Table 1) randomized 6609 CKD patients with a mean eGFR of 37.5 mL/ min/1.73 m 2 , who were randomly assigned to 10 mg/day empagliflozin or a placebo [98].”
BackgroundMethodInfluentialKetoacidosis and SGLT2 Inhibitors: A Narrative Review
Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., et al. (2024) · Metabolites · doi:10.3390/metabo14050264 · Cited by 75
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
Endothelial dysfunction in chronic kidney disease: a clinical perspective
Cho, M. E., Brunt, V. E., Shiu, Y.-T., & Bunsawat, K. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00908.2024 · Cited by 61
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 78
“80 Moreover, the DAPA-CKD study has suggested that dapagliflozin decreases the risk of worsening renal function, terminal-stage renal disease, and death from renal or cardiovascular diseases in patients with CKD (with or without T2DM) and has indicated similar effects in the older subgroup and the…”
BackgroundMadero, M., Chertow, G. M., & Mark, P. B. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100851 · Cited by 81
Kushner, P. R., Khunti, K., Cebrián, A., & Deed, G. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02957-z · Cited by 105
Mahaffey, K. W., Tuttle, K. R., Arici, M., Baeres, F. M. M., Bakris, G. L., Charytan, D. M., Cherney, D. Z. I., Chernin, G., Correa‐Rotter, R., Gumprecht, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae613 · Cited by 78
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
Madero, M., Levin, A., Ahmed, S. B., Carrero, J. J., Foster, B. J., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01926 · Cited by 90
Ortíz, A., Guerra, J. M. A., Chan, J. C. N., Jha, V., Kramer, H., Nicholas, S. B., Pavkov, M. E., Wanner, C., Wong, L. P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.005 · Cited by 91
Riley, D. R., Essa, H., Austin, P., Preston, F., Kargbo, I., Ibarburu, G. H., Ghuman, R., Cuthbertson, D. J., Lip, G. Y. H., & Alam, U. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15185 · Cited by 59
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Chong, K., Chang, J. K.-J., & Chuang, L. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12800 · Cited by 84
“20 (Figure 2).”
Chen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 83
Floege, J., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarchi, H., Balk, E. M., Gordon, C. E., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.003 · Cited by 91
Sarafidis, P. A., Agarwal, R., Pitt, B., Wanner, C., Filippatos, G. S., Boletis, J., Tuttle, K. R., Ruilope, L. M., Rossing, P. R., Toto, R., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000149 · Cited by 64
“Kidney and urinary disorders 86 (20) 105 (23) AKI 24 (6) 33 (7) Worsening kidney function Leading to discontinuation 7 (2) 9 (2) Leading to hospitalization 17 (4) 18 (4) Hyperkalemia 115 (26) 56 (13) Leading to discontinuation 14 (3) 10 (2) Leading to hospitalization 13 (3) 5 (1)”
BackgroundVerma, A., Schmidt, I. M., Claudel, S. E., Pálsson, R., Waikar, S. S., & Srivastava, A. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2814 · Cited by 76
Hobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Kim, S., Kwon, J., Jones, L., Hirst, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03263-5 · Cited by 76
SGLT2 inhibitors: Beyond glycemic control
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel‐Rahman, E. M., & Awad, A. S. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100335 · Cited by 89
“EMPA-KIDNEY, DAPA-CKD, and DELIVER trials included 46.2 %, 67.6 %, and 45 % diabetic population [62 – 63 , 65 ].”
InfluentialUpdate on the Pathogenesis, Diagnosis, and Treatment of Diabetic Tubulopathy
Liu, D., Chen, X., He, W., Lu, M., Li, Q., Zhang, S., Xie, J., Zhang, Y., & Wang, W. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-23-00029 · Cited by 68
Forbes, A., Hinton, W., Feher, M. D., Elson, W. H. D., Joy, M., Ordóñez-Mena, J. M., Fan, X., Cole, N. I., Banerjee, D., Suckling, R., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102426 · Cited by 57
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 77
Lang, F., Teruya, S. L., Weinsaft, A., Cuomo, M., Santos, A. M., Nalbandian, A., Bampatsias, D., & Maurer, M. S. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3198 · Cited by 57
Yen, F., Hwu, C., Liu, J., Wu, Y., Chong, K., & Hsu, C. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1874 · Cited by 68
Targeting the Endothelin A Receptor in IgA Nephropathy
Kohan, D. E., Barratt, J., Heerspink, H. J. L., Campbell, K. N., Camargo, M., Ogbaa, I., Haile-Meskale, R., Rizk, D. V., & King, A. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.07.023 · Cited by 54
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Pitt, B., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.026 · Cited by 64
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 101
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 66
“These fi ndings are analogous to results from large randomized trials in heart failure populations that included a large proportion of patients with CKD and low eGFR and demonstrated consistent effects of SGLT2 inhibitors on cardiovascular death or hospitalization for heart failure irrespective of…”
InfluentialHow do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Wanner, C., Nangaku, M., Kraus, B. J., Zinman, B., Mattheus, M., Hantel, S., Schumacher, M. C., Ohneberg, K., Schmoor, C., & Inzucchi, S. E. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae032 · Cited by 59
Mårup, F. H., Thomsen, M. B., & Birn, H. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad249 · Cited by 63
“A renal protective effect of SGLT2i has been confirmed in both diabetic and non-diabetic CKD patients [2 –4 ].”
BackgroundNovel Treatment Paradigms: Primary IgA Nephropathy
Selvaskandan, H., Barratt, J., & Cheung, C. K. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.026 · Cited by 59
Berg, D. D., Patel, S. M., Haller, P. M., Cange, A. L., Palazzolo, M. G., Bellavia, A., Kuder, J., Desai, A. S., Inzucchi, S. E., McMurray, J. J. V., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.076575 · Cited by 69
Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101419 · Cited by 51
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Mazzieri, A., Porcellati, F., Timio, F., & Reboldi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073969 · Cited by 64
“Additionally, in the proximal tubule, the activation of GLP1-R leads to the onset of the cAMP signaling cascade with phosphorylation of Na + /H + exchanger isotope 3 (NHE3) and reduction of its function.”
BackgroundRenin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 66
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Powell, D. R., Davies, M. J., Banks, P. L., & Agarwal, R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15019 · Cited by 55
Alport Syndrome: Clinical Spectrum and Therapeutic Advances
Gregorio, V. D., Çaparali, E. B., Shojaei, A., Ricardo, S., & Barua, M. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100631 · Cited by 66
“Recently the EMPA-KIDNEY trial with 6,609 chronic kidney disease patients enrolled to assess the efficacy of empagliflozin was reported.(96) The mean age of the participants was 63.”
BackgroundInfluentialBeyond glycemia: Comparing tirzepatide to GLP-1 analogues
Andraos, J., Muhar, H. K., & Smith, S. R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09825-1 · Cited by 59
Sirtuins in kidney health and disease
Perico, L., Remuzzi, G., & Benigni, A. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00806-4 · Cited by 61
“A high prevalence of vascular calcification contributes to cardiovascular morbidity and mortality in patients with CKD 184 .”
InfluentialThe anti-inflammatory and immunological properties of SGLT-2 inhibitors
Bendotti, G., Montefusco, L. B., Pastore, I., Lazzaroni, E., Lunati, M. E., & Fiorina, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02162-9 · Cited by 53
Awdishu, L., Maxson, R., Gratt, C., Rubenzik, T. T., & Battistella, M. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf044 · Cited by 71
“18,23 Clinical trials demonstrating the efficacy and safety of a pillar approach to medication management in CKD are lacking.”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Caravaca‐Fontán, F., Stevens, K., Padrón, M., Huerta, A., Montomoli, M., Villa, J., González, F., Vega, C., Mendoza, M. L., Fernández, L., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad175 · Cited by 57
The Treatment of Primary IgA Nephropathy: Change, Change, Change
Caster, D. J., & Lafayette, R. A. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.08.007 · Cited by 55
Bidulka, P., Lugo-Palacios, D. G., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., Bartlett, J. W., Nitsch, D., Charlton, P., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077097 · Cited by 63
Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.023 · Cited by 49
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020279 · Cited by 63
Sex and gender differences in the management of chronic kidney disease and hypertension
Mayne, K. J., Sullivan, M. K., & Lees, J. S. (2023) · Journal of Human Hypertension · doi:10.1038/s41371-023-00843-9 · Cited by 54
“73m(2) irrespective of blood pressure, yet there is emerging evidence to suggest larger effects in those with higher levels of albuminuria [25].”
BackgroundPrescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin, J., Xu, Y., Chang, A. R., Carrero, J. J., Flaherty, C. M., Mukhopadhyay, A., Inker, L. A., Blecker, S., Horwitz, L. I., & Grams, M. E. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.057 · Cited by 67
Peter, W. L. S., Bzowyckyj, A. S., Anderson-Haag, T. L., Awdishu, L., Blackman, M., Bland, A., Chan, E., Chmielewski, C. M., Delgado, C., Eyler, R. F., et al. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae317 · Cited by 56
Miyamoto, Y., Honda, A., Yokose, S., Nagata, M., & Miyamoto, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062253 · Cited by 51
An Update on Current Therapeutic Options in IgA Nephropathy
Lim, R. S., Yeo, S. C., Barratt, J., & Rizk, D. V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040947 · Cited by 46
Martínez, J. J. G., Górriz, J. L., Cuenca, A. M. C., Conde, A. C., & Velasco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216509 · Cited by 62
Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
Tuttle, K. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167700 · Cited by 48
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 49
Heart Failure in Patients with Chronic Kidney Disease
Xanthopoulos, A. V., Papamichail, A., Briasoulis, Α., Loritis, K., Bourazana, A., Magouliotis, D. E., Sarafidis, P. A., Stefanidis, I., Skoularigis, J. S., & Triposkiadis, F. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186105 · Cited by 68
“73 m2 or less, a sustained decrease in eGFR of 40% or more from baseline, or death from renal causes) compared with placebo [91].”
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
Kounatidis, D. C., Vallianou, N. G., Evangelopoulos, A. A., Vlahodimitris, I., Grivakou, E., Kotsi, E., Dimitriou, K., Skourtis, A., & Mourouzis, I. S. (2023) · Nutrients · doi:10.3390/nu15102294 · Cited by 44
“In humans, empagliflozin was the first drug in the class of SGLT-2 inhibitors that was documented to have beneficial effects among patients with T2DM and CKD.”
BackgroundMethodInfluentialLuo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 45
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 48
Membranous nephropathy treatment standard
Radhakrishnan, Y., Zand, L., Sethi, S. M., & Fervenza, F. C. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad225 · Cited by 52
Therapy of IgA nephropathy: time for a paradigm change
Barratt, J., Lafayette, R. A., & Floege, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1461879 · Cited by 51
Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
Neuen, B. L., Yeung, E. K., Rangaswami, J., & Vaduganathan, M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae258 · Cited by 58
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 53
Young, K., McInnes, E. H., Massey, R. J., Kahkoska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00359-w · Cited by 54
Kani, R., Watanabe, A., Miyamoto, Y., Ejiri, K., Iwagami, M., Takagi, H., Slipczuk, L. N., Tsugawa, Y., Aikawa, T., & Kuno, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031805 · Cited by 49
Theodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.